<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02260570</url>
  </required_header>
  <id_info>
    <org_study_id>D0825-I</org_study_id>
    <secondary_id>1I01RX000825-01</secondary_id>
    <nct_id>NCT02260570</nct_id>
  </id_info>
  <brief_title>Remediation of Impaired Self-Regulation in Patients With Mild TBI</brief_title>
  <official_title>Remediation of Impaired Self-Regulation in Patients With Mild TBI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Berkeley</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ability to regulate impulses enables us to plan for the future, to maintain focus in the&#xD;
      face of distractions (i.e. to encode memories), and to manage emotions. This self regulation&#xD;
      can be compromised in individuals who have a history of mild traumatic brain injury and&#xD;
      co-occurring disorders. In this study the investigators are using functional MRI scanning to&#xD;
      understand how memory and self regulation are expressed in the brains of people with a&#xD;
      history of mild traumatic brain injury. The investigators are also testing whether the&#xD;
      medication tolcapone may improve memory and self regulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this randomized, double-blind, placebo-controlled, crossover cognitive neuroscience study,&#xD;
      the investigators are evaluating whether the COMT inhibitor tolcapone impacts memory and self&#xD;
      regulation, as measured both behaviorally (via cognitive testing) and neurophysiologically&#xD;
      (via functional MRI). A new study arm that does not include use of tolcapone, nominally&#xD;
      equivalent to the placebo arm only, is now also included to address performance on cognitive&#xD;
      testing alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2015</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Oxygen Level Dependent (BOLD) brain signal measured using functional MRI</measure>
    <time_frame>Approximately 60-240 minutes following tolcapone/placebo administration</time_frame>
    <description>BOLD signal provides an indirect measure of brain activity during cognitive testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance on Cognitive Testing</measure>
    <time_frame>Approximately 60-240 minutes following tolcapone/placebo administration</time_frame>
    <description>Tasks to assess cognition will be performed while subjects are in the MRI scanner</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Mild Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Functional MRI Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This cognitive science study consists of a single &quot;arm&quot; in which all subjects receive both tolcapone and placebo in randomized, double-blind, counterbalanced, crossover fashion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolcapone</intervention_name>
    <description>COMT Inhibitor</description>
    <arm_group_label>Functional MRI Arm</arm_group_label>
    <other_name>Tasmar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A pill that contains no active ingredient</description>
    <arm_group_label>Functional MRI Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Veteran ages 18-50 and in general good health;&#xD;
&#xD;
          -  Able to read English at a 6th grade level;&#xD;
&#xD;
          -  Able to provide written informed consent;&#xD;
&#xD;
          -  Normal or corrected to normal visual acuity;&#xD;
&#xD;
          -  Stable doses of all medications (2 weeks or greater);&#xD;
&#xD;
          -  History of mild traumatic brain injury greater than 6 months prior to participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to MRI scanning;&#xD;
&#xD;
          -  Inability to complete basic fMRI requirements;&#xD;
&#xD;
          -  History of brain surgery or penetrating brain injury;&#xD;
&#xD;
          -  Uncontrolled blood pressure (low or high);&#xD;
&#xD;
          -  Contraindications to tolcapone use (not required for subjects who participate only in&#xD;
             the study arm that does not include study medication);&#xD;
&#xD;
          -  Use of medications or drugs with dopamine-related actions within 30 days;&#xD;
&#xD;
          -  Active substance abuse or dependence;&#xD;
&#xD;
          -  Clinically severe medical illness requiring treatment;&#xD;
&#xD;
          -  History of psychiatric hospitalization (past 1 year) or suicide attempt (past 5&#xD;
             years);&#xD;
&#xD;
          -  Seizures greater than 4 weeks after TBI event or seizures requiring active treatment;&#xD;
&#xD;
          -  History of brain tumor, stroke, Alzheimer's disease, aneurysm rupture, or multiple&#xD;
             sclerosis;&#xD;
&#xD;
          -  History of schizophrenia, ADHD or psychiatric diagnosis EXCEPT depression or PTSD&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew S Kayser, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Northern California Health Care System, Mather, CA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Northern California Health Care System, Mather, CA</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 6, 2014</study_first_submitted>
  <study_first_submitted_qc>October 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2014</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>concussion</keyword>
  <keyword>traumatic brain injury</keyword>
  <keyword>MRI</keyword>
  <keyword>memory</keyword>
  <keyword>tolcapone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Brain Concussion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolcapone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

